or Try an Advanced Search...

    Technical Analysis for ACST - Acasti Pharma, Inc.

    Grade Last Price % Change Price Change
    D 2.88 1.05% 0.03
    ACST closed up 1.05 percent on Tuesday, April 23, 2024, on 15 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical ACST trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Inside Day Range Contraction 0.00%
    Below Lower BB Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness 1.05%
    Below Lower BB Weakness 1.05%
    Down 3 Days in a Row Weakness 1.05%
    Down 4 Days in a Row Weakness 1.05%
    Older End-of-Day Signals for ACST ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 12 hours ago
    Possible Inside Day about 12 hours ago
    60 Minute Opening Range Breakout about 16 hours ago
    60 Minute Opening Range Breakout 1 day ago
    Up 1% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ACST Chart by TradingView
    Basic chart:

    Profile

    Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for abnormalities in blood lipids, and the treatment and prevention of cardiovascular disorders. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cardiovascular Disease Lipid Drug Products Metabolic Disorders Fatty Acids Triglyceride Hypertriglyceridemia Medical Food Onemia

    Is ACST a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 24 12 Best Biotech Penny Stocks to Invest In
    Jan 18 Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Dec 13 Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
    Nov 13 Acasti Pharma GAAP EPS of -$0.43
    Nov 13 Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
    Oct 23 Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
    See more ACST news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.834
    52 Week Low 1.72
    Average Volume 29,933
    200-Day Moving Average 2.60
    50-Day Moving Average 3.29
    20-Day Moving Average 3.29
    10-Day Moving Average 3.18
    Average True Range 0.11
    RSI (14) 21.26
    ADX 30.04
    +DI 8.65
    -DI 33.84
    Chandelier Exit (Long, 3 ATRs) 3.16
    Chandelier Exit (Short, 3 ATRs) 3.15
    Upper Bollinger Bands 3.69
    Lower Bollinger Band 2.90
    Percent B (%b) -0.02
    BandWidth 24.09
    MACD Line -0.09
    MACD Signal Line -0.02
    MACD Histogram -0.0739
    Fundamentals Value
    Market Cap 27.07 Million
    Num Shares 9.4 Million
    EPS -5.65
    Price-to-Earnings (P/E) Ratio -0.51
    Price-to-Sales 208.39
    Price-to-Book 0.35
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.93
    Resistance 3 (R3) 2.92 2.90 2.92
    Resistance 2 (R2) 2.90 2.89 2.90 2.91
    Resistance 1 (R1) 2.89 2.88 2.90 2.90 2.91
    Pivot Point 2.87 2.87 2.87 2.87 2.87
    Support 1 (S1) 2.86 2.86 2.87 2.87 2.85
    Support 2 (S2) 2.84 2.85 2.84 2.85
    Support 3 (S3) 2.83 2.84 2.84
    Support 4 (S4) 2.84